0
2022
Immune Checkpoint Inhibitors Market

Immune Checkpoint Inhibitors Market

by Type (PD-1 Inhibitors, PD-L1 Inhibitors and CTLA-4 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma and other application): Global Opportunity Analysis and Industry Forecast, 2021-2030

Report Code: A03382
Pages: 160
Jan 2022 | 20871 Views
Author(s) : Vikita Thakur , Onkar Sumant
Tables: 54
Charts: 48
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Immune Checkpoint Inhibitors Market

Request Now !

Immune Checkpoint Inhibitors Market Synopsis | 2030

The global immune checkpoint inhibitors market was valued at $29,803.71 million in 2020, and is projected to reach $1,40,890.10 million by 2030, registering a CAGR of 16.8% from 2021 to 2030.

The immune checkpoint inhibitors market was negatively impacted by the COVID-19 pandemic. Owing to decline in number of cancer patient visits in hospitals and clinics for immune checkpoint inhibitors therapies which lead to decline in the demand of immune checkpoint inhibitors products. For instance, according to AstraZenca PLC, Opidivo (immune checkpoint inhibitor) registered a 5.6 % decline in

Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumor cells as they affect functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins including CTLA-4 (cytotoxic T lymphocyte associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed death ligand 1). Immune checkpoint inhibitor targets checkpoint proteins and assists the immune system to recognize and attack cancer cells. 

Immune-checkpoint-Inhibitors-Market

Immune checkpoint inhibitors are expected to exhibit significant market growth during the forecast period, owing to growth in demand for ideal therapeutics for treatment of cancer, favorable reimbursement policies provided by manufacturers & insurance providers in some countries, and surge in prevalence of cancer across the globe. The key factors driving growth of Immune Checkpoint Inhibitors market growth are attributed to increase in incidences of different forms of cancer, surge in awareness of checkpoint inhibitors for treatment of cancer, higher number of R&D studies, and surge in adoption of immune checkpoint inhibitor drugs. In addition, growth in geriatric population and technological advancements in screening & diagnosis of cancer further drives the market growth. However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth.

The immune checkpoint inhibitors market is segmented on the basis of type, application, and region. On the basis of, the market is classified as CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. According application, it is categorized into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

What is the Impact of COVID-19 on Immune Checkpoint Inhibitors Market?

Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans. 

After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement. Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, only a few vaccines that received emergency approvals for COVID-19 prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns. 

The overall impact of COVID-19 remains negative on the immune checkpoint inhibitor market, owing to decline in number of cancer patients visits in hospitals and clinics for immune checkpoint inhibitor therapy (ICI) which lead to decline in the demand of Immune checkpoint inhibitors products. For instance, according to NCBI in 2020 around 50% of patient decrease is reported for cancer care in U.S. and overall cancer therapies are declined by 50% during COVID-19. Furthermore, WHO issued guidelines regarding the nonessential planned therapies such as for cancer and procedures based on the need of critical situations? The guidelines suggest to provide emergency services to patients who require urgent attention and postpone the therapies and surgery if not urgent, which lead to decline in the demand for immune check point products in the market. 

In addition, owing to the outbreak most of the markets are experiencing a decline especially immune checkpoint inhibitors market. For instance, according to AstraZeneca plc, Opidivo (immune checkpoint inhibitor) registered a 5.6% decline in 2020 due to decline in no of cancer patients visit in clinics and hospitals during COVID-19 which led to decline in the demand for immune check point products in the market.

By Type Segment Review

By type, the immune checkpoint inhibitors market is divided into CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. The PD-1 inhibitor segment was the major revenue contributor in 2020, and is anticipated to continue this trend during the forecast period, owing due to increase in adoption of PD-1 inhibitors such as pembrolizumab and nivolumab globally. On the other side, the demand for PD-L1 inhibitor is projected to exhibit the fastest immune checkpoint inhibitors market growth during the forecast period, owing to rise in use of durvalumab & avelumab and surge in R&D studies for PD-L1 inhibitors. 

Immune Checkpoint Inhibitors Market
By Type

Your browser does not support the canvas element.

PD-1 inhibitor segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By Application Segment Review

By application, the immune checkpoint inhibitors market is classified as lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. The lung cancer segment presently dominates the market, and is expected to remain dominant during the forecast period, due owing to increase in use of immune checkpoint inhibitors for the treatment of lung cancer and surge in prevalence of lung cancer globally. However, the bladder cancer segment is projected to show fastest growth during the forecast period, due owing to increase in incidences of bladder cancer.

Immune Checkpoint Inhibitors Market
By Application

Your browser does not support the canvas element.

Lung cancer segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By Region segment review

By region, the Immune checkpoint inhibitors market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America dominated the market in 2020, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. The research activities for immune checkpoints inhibitors are soaring in North America due to significant infrastructure for developmental research, availability of substantial research funds and growing government initiatives towards immune checkpoint inhibitors are anticipated to drive the market growth.

Immune Checkpoint Inhibitors Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America holds a dominant position in 2020 and continue to maintain lead in the forecast year

Get more information on this report : Request Sample Pages

This report provides comprehensive competitive analysis and profiles of prominent market players such as Key players operating in the global immune checkpoint inhibitors market are, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.) GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), and BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd. 

Key Benefits for Stakeholders

  • This report provides a detailed quantitative analysis of the current Immune checkpoint inhibitors market trends and forecast estimations from 2020 to 2030, which assists to identify the prevailing market opportunities. 
  • An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
  • The projections in this report are made by analyzing the current trends and future market potential from 2021 to 2030, in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the Immune checkpoint inhibitors market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the Immune checkpoint inhibitors market.

Immune Checkpoint Inhibitors Market Report Highlights

Aspects Details
By Type
  • CTLA-4 Inhibitor
  • PD-1 Inhibitor
  • PD-L1 Inhibitor
By Application
  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Hodgkin lymphoma
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Rest of LAMEA)
By KEY PLAYERS
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company (ARMO Biosciences.)
  • GlaxoSmithKline PLC
  • F. Hoffmann-La Roche Ltd. (Genentech Inc.,)
  • Sanofi
  • Merck & Co., Inc.
  • Merck KGaA (EMD Serono Inc.)
  • BeiGene Ltd
  • Shanghai Jhunsi Biosciences Ltd.
 

Loading Table Of Content...


 
 

In accordance with several interviews conducted, top-level CXOs agree that the utilization of immune checkpoint inhibitors market is anticipated to witness a significant rise with technological advancements and increase in prevalence of various types of cancer such as lung cancer, bladder cancer and others. Recent innovations and constant development in this field have fuelled the market growth, also Increase in interest of healthcare providers owing to several benefits offered by immune checkpoint inhibitors is boosting the market.

According to the CXOs, rise in diagnosis of cancer in developing countries, surge in R&D studies, and growth in adoption of immune checkpoint inhibitors is projected to supplement the market growth during the forecast period. However, complications and higher cost associated with the use of immune checkpoint inhibitors are expected to hinder the market growth.

In addition, North America is expected to remain dominant during the forecast period due to surge in use of immune checkpoint inhibitors owing to presence of advanced healthcare facilities and higher number of target population. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period due to developments in healthcare infrastructure with rise in demand for immune checkpoint inhibitors.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of immune checkpoint inhibitors market is $1,40,890.10 Million in 2030

A. The forecast period in the report is from 2021 to 2030

A. The market value of immune checkpoint inhibitors in 2020 was 29,803.70 million in 2020

A. The base year for the report is 2020

A. Yes, immune checkpoint inhibitors market companies are profiled in the report

A. The top companies that hold the market share in immune checkpoint inhibitors market are Merck Kgaa, Merck Co & Inc, Astrazenca Plc, F hoffman La Roche and Elly Lilly and company

A. No, there is no value chain analysis provided in the immune checkpoint inhibitors market report

A. The key trends in the immune checkpoint inhibitors market are increase in prevalence of chronic disease such as cancer along with rise in elderly population are the key factors driving the market growth.t

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Free Sample

OR

Purchase Full Report of
Immune Checkpoint Inhibitors Market

Start reading instantly.
This Report and over 18,822+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Jan 2023 - Jan 2024)
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2023 - Jan 2024)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2023 - Jan 2024)
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2023 - Jan 2024)
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jan 2023 - Jan 2024)
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers